A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout.

Trial Profile

A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2014

At a glance

  • Drugs Arhalofenate (Primary)
  • Indications Gout
  • Focus Therapeutic Use
  • Sponsors CymaBay Therapeutics
  • Most Recent Events

    • 01 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 24 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top